Last reviewed · How we verify
Synercid (DALFOPRISTIN)
Synercid (DALFOPRISTIN) is a Streptogramin Antibacterial drug, originally developed by Rhône-Poulenc Rorer and currently owned by Pfizer. It is a small molecule modality, approved by the FDA in 1999 for treating complicated skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes, and Vancomycin-resistant enterococcus. Synercid works by inhibiting protein synthesis in bacteria, ultimately leading to cell death. It has a short half-life of 0.74 hours. Synercid is a patented drug, and its commercial status is not generic.
At a glance
| Generic name | DALFOPRISTIN |
|---|---|
| Drug class | Streptogramin Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
- Complicated Skin and Skin Structure Staphylococcus Aureus Infection
- Streptococcus pyogenes infection
- Vancomycin resistant enterococcus
Common side effects
Key clinical trials
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synercid CI brief — competitive landscape report
- Synercid updates RSS · CI watch RSS